Stock Analysis
Genomma Lab Internacional. de Second Quarter 2024 Earnings: Beats Expectations
Genomma Lab Internacional. de (BMV:LABB) Second Quarter 2024 Results
Key Financial Results
- Revenue: Mex$4.65b (up 6.4% from 2Q 2023).
- Net income: Mex$631.6m (up 51% from 2Q 2023).
- Profit margin: 14% (up from 9.6% in 2Q 2023). The increase in margin was driven by higher revenue.
- EPS: Mex$0.67 (up from Mex$0.43 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Genomma Lab Internacional. de Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 4.6%. Earnings per share (EPS) also surpassed analyst estimates by 45%.
Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Global Pharmaceuticals industry.
Performance of the market in Mexico.
The company's shares are up 5.8% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for Genomma Lab Internacional. de (of which 1 shouldn't be ignored!) you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About BMV:LAB B
Genomma Lab Internacional. de
Provides pharmaceutical and personal care products primarily in Latin America.
